As Ozempic costs fall, demand for weight-loss drugs is set to surge

Published 6 Min Read

GLP-1 injection pen held by woman in front of abdomen.
Adobe Stock

  • Key Insight: Learn how Novo Nordisk’s price cuts could expand employer GLP‑1 coverage strategies.
  • What’s at Stake: Rising utilization may significantly shift benefits spend and competitive employee recruitment.
  • Supporting Data: Novo Nordisk cuts Ozempic/Wegovy to $675 monthly starting Jan 1, 2027.
    Source: Bullets generated by AI with editorial review

Companies are expecting a surge in demand for weight loss drugs after one of the world’s leading pharmaceutical giants announced a price cut of up to 50% starting next year. 

Jimmy Nesbitt
Reporter

Jimmy Nesbitt is a reporter at Employee Benefit News, where he covers the evolving landscape of workplace benefits, healthcare, retirement, financial wellness and related policy issues. His career … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form